No Data
No Data
H.C. Wainwright Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Day One Biopharmaceuticals Poised for Growth With Strategic Partnerships and Promising Ojemda Prospects
Capital One Financial Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Strong Buy Rating for Day One Biopharmaceuticals Amid Strategic Partnership and Promising Financial Health
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $39
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Day One Biopharmaceuticals (DAWN)